Milestone Pharmaceuticals Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MIST in the last 30 days.
See all $MIST insider activity →Milestone Pharmaceuticals (MIST) announced China's approval of etripamil nasal spray for treating PSVT in adults, triggering a $2M milestone payment. Everest Medicines holds exclusive rights in Greater China, with up to $98M in potential milestones and 18% royalties. The approval was based on Phase 3 study data showing significant efficacy over placebo.
Milestone Pharmaceuticals (MIST) began a Phase 3 trial for etripamil nasal spray to treat AFib-RVR. The study aims to assess rapid ventricular rate reduction and symptom improvement in unsupervised settings. MIST seeks FDA approval based on existing safety data. The stock traded between $1.00 and $3.06 in the past year, closing at $1.03 on Thursday.
Milestone Pharmaceuticals (MIST) shares rose 3.9% after enrolling the first patient in its Phase 3 ReVeRA-301 trial for etripamil in treating AFib-RVR. The trial evaluates the same 70 mg dose approved for PSVT. The study aims to enroll 150 patients, with primary and secondary endpoints focused on ventricular rate reduction and symptom improvement. Milestone seeks FDA approval for home use. AFib affects 6 million U.S. patients, with projected economic costs rising to $174.8 billion by 2050, accor
Over the past 7 days, alphai's AI scored 2 news stories mentioning MIST (Milestone Pharmaceuticals Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent MIST coverage spans earnings, technology and regulation.
Regulatory approval in a large market unlocks significant revenue potential and milestone payments, likely boosting the stock.
Phase 3 initiation validates earlier Phase 2 data and could unlock a new indication for an already approved product.
First‑patient enrollment signals progress toward potential FDA approval, likely supporting short‑term upside.
Earnings miss versus prior year loss but revenue growth and expanded coverage may support near‑term price stability.
Improving payer coverage and a near-term first-patient expectation for the AFib-RVR registrational trial are the key incremental catalysts for MIST.
alphai scores every news story that mentions MIST with an AI model for sentiment and relevance, and aggregates insider trades from Milestone Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Milestone Pharmaceuticals (MIST) announced China's approval of etripamil nasal spray for treating PSVT in adults, triggering a $2M milestone payment. Everest Medicines holds exclusive rights in Greater China, with up to $98M in potential milestones and 18% royalties. The approval was based on Phase 3 study data showing significant efficacy over placebo.
2 min readMilestone Pharmaceuticals (MIST) began a Phase 3 trial for etripamil nasal spray to treat AFib-RVR. The study aims to assess rapid ventricular rate reduction and symptom improvement in unsupervised settings. MIST seeks FDA approval based on existing safety data. The stock traded between $1.00 and $3.06 in the past year, closing at $1.03 on Thursday.
2 min readMilestone Pharmaceuticals (MIST) shares rose 3.9% after enrolling the first patient in its Phase 3 ReVeRA-301 trial for etripamil in treating AFib-RVR. The trial evaluates the same 70 mg dose approved for PSVT. The study aims to enroll 150 patients, with primary and secondary endpoints focused on ventricular rate reduction and symptom improvement. Milestone seeks FDA approval for home use. AFib affects 6 million U.S. patients, with projected economic costs rising to $174.8 billion by 2050, accor
2 min readMilestone Pharmaceuticals (MIST) reported Q2 2026 earnings, with product revenue of $559,000 and a net loss of $28.6 million. The company saw a fourfold increase in prescriptions and 50% commercial insurance coverage for CARDAMYST. Management expects cash runway into 2H 2027 and anticipates Medicare coverage in 2027. The Phase III trial for AFib-RVR is underway, targeting a larger patient population.
3 min readMilestone Pharmaceuticals (NASDAQ:MIST) reported Q2 product revenue of $0.6M versus none a year earlier, and a net loss of $28.6M ($0.21/share). Management said CARDAMYST prescriber uptake and payer coverage improved, with coverage at about 25% of commercially insured lives and plans to expand. Milestone also started registrational enrollment for ReVeRA-301 etripamil in AFib-RVR.
6 min readMilestone Pharmaceuticals (Nasdaq: MIST) reported Q2 2026 results and a corporate update. It said CARDAMYST (etripamil) prescriptions and coverage expanded, with cash, cash equivalents and short-term investments of $170.6 million as of June 30, 2026. The Phase 3 ReVeRA-301 AFib-RVR trial opened, and EMA/China reviews are ongoing. Q2 net loss was $28.6 million.
7 min readMilestone Pharmaceuticals Inc. (MIST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST ® (etripamil) nasal spray Phase
6 min readRaymond James issued an earnings preview for seven commercial-stage biopharma firms ahead of Q2 2026 results. It highlighted Insmed (INSM) launch growth, United Therapeutics (UTHR) Tyvaso revenue of about $480M-$490M, Jazz (JAZZ) potential beat, Ionis (IONS) Tryngolza value, PTC (PTCT) $150M-$160M Q2 sales, Tonix (TNXP) access expansion, and Milestone (MIST) Cardamyst trajectory.
2 min readMilestone Pharmaceuticals (Nasdaq: MIST) said it granted 288,000 stock options under its 2021 Inducement Plan to hire six new employees. Options were granted July 1, 2026 with an exercise price of $1.32 per share (the closing price that day). Vesting is over four years: 25% after one year, then monthly installments for 36 months, subject to continued service.
2 min readMilestone Pharmaceuticals Inc. (MIST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2617859d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Milestone Pharmaceuticals Inc. 2019 Equity Incentive Plan, As Amended MILESTONE PHARMACEUTICALS INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 10, 2019 APPROVED BY THE SHAREHOLDERS: APRIL 29, 201
4 min read
